At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 33 enrolled
Drug / intervention
Fidaxomicin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exploratory Study of Impact of Oral Metronidazole, Vancomycin and Fidaxomicin on the Extent and Quantity of Host Carriage and Environmental Contamination With C. Difficile
In Brief
A Phase 4 clinical trial evaluating Fidaxomicin, Metronidazole, and 1 other intervention for C. Difficile and 2 related conditions. Completed, enrolled 33 participants across 1 site.
Detailed Summary
The overall aim is to characterize and to compare the extent and quantity of C. difficile stool shedding, perianal colonization and environmental contamination in patients who received oral fidaxomicin, oral metronidazole, or oral vancomycin. This is a prospective, randomized, microbiologic and molecular, study of environmental contamination from patients with proven C. difficile associated diarrhea (CDAD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsC. Difficile, Diarrhea, Enterocolitis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 2014
Enrollment StartJun 2014
Primary CompletionJun 2017
TodayJul 2026
First PostedFeb 6, 2014
Enrollment StartJun 10, 2014
Primary CompletionJun 27, 2017
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 12.4 years ago
Interventions
Fidaxomicindrug
Metronidazoledrug
Vancomycindrug